John C. L. Erve

Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates

David M. Stresser, Andrew P. Blanchard, Stephanie D. Turner et al. · Drug Metabolism and Disposition · 2000 · 276 citations

Medicine, Pharmacokinetics, Pharmacology +17

Spectral accuracy of molecular ions in an LTQ/Orbitrap mass spectrometer and implications for elemental composition determination

John C. L. Erve, M. F. Gu, Yongdong Wang et al. · Journal of the American Society for Mass Spectrometry · 2009 · 136 citations

Natural Sciences, Biochemistry, Chemistry +17

HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE

David M. Stresser, Marc I. Broudy, Thuy Ho et al. · Drug Metabolism and Disposition · 2004 · 128 citations

Medicine, Medicinal Chemistry, Pharmacology +15

<i>In vitro</i>and<i>in vivo</i>pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin

Mark P. Grillo, John C. L. Erve, Ryan A. Dick et al. · Xenobiotica · 2018 · 104 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate

Yong-Kang Zhang, Jacob J. Plattner, Eric E. Easom et al. · Journal of Medicinal Chemistry · 2017 · 61 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17